Get started
Author

Menghan Su

Efgartigimod versus intravenous immunoglobulin in the treatment of patients with impending myasthenic crisis
2024 · Jing Ma, Huiqiu Zhang, et al. · Scientific Reports · 26
PDF
Possibility of PD-1/PD-L1 Inhibitors for the Treatment of Patients with Chronic Hepatitis B Infection
2023 · Menghan Su, Ting Ye, et al. · Digestive Diseases · 13
The difference of variation types between late-onset multiple acyl-CoA dehydrogenase deficiency patients carrying biallelic and single heterozygous variations in ETFDH: a systematic review and meta-analysis
2025 · Huiqiu Zhang, Jing Ma, et al. · Orphanet Journal of Rare Diseases · 5
PDF
Comparison of intravenous efgartigimod and intravenous immunoglobulin in patients with Guillain–Barré syndrome
2025 · Huiqiu Zhang, Feipeng Zhai, et al. · Orphanet Journal of Rare Diseases · 3
PDF
Comparison between mono-tacrolimus and mono-prednisone in the treatment of ocular myasthenia gravis: a retrospective, observational cohort study
2026 · Ziling Wang, Jinna Li, et al. · Frontiers in Immunology
PDF
Hyperhomocysteinemia in late-onset MADD: high prevalence and exacerbation of lipid deposition
2026 · Junsen Zhao, Menghan Su, et al. · Orphanet Journal of Rare Diseases
Hyperhomocysteinemia promotes lipid deposition in skeletal muscle
2026 · Menghan Su, Jiaqi Jiao, et al. · Frontiers in Neurology
Genotype-environment interaction drives the onset of riboflavin-responsive multiple acyl-CoA dehydrogenase deficiency in carriers of single heterozygous ETFDH variants
2026 · Jing Ma, Huiqiu Zhang, et al. · Cell Communication and Signaling
Works count: 32
Citation count: 47
H-index: 3
I10-index: 2
Year
Topic
Type